Cutler Group LP Cogent Biosciences, Inc. Call Options Transaction History

Cutler Group LP

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 Apr 19, 2024	BUY	$4.38 - $9.02 $14,892 - $30,668	3,400 Added 3400.0%	3,500 $1,000
Q4 2023 Jan 18, 2024	BUY	$4.06 - $10.08 $405 - $1,008	100 New	100 $0
Q4 2022 Feb 07, 2023	BUY	$10.65 - $14.84 $2,130 - $2,968	200 Added 66.67%	500 $0
Q3 2022 Oct 25, 2022	SELL	$9.39 - $16.99 $86,388 - $156,308	-9,200 Reduced 96.84%	300 $0
Q2 2022 Aug 04, 2022	BUY	$3.92 - $9.73 $37,240 - $92,435	9,500 New	9,500 $4,000

172

113M

56.7K

40.4K

Ticker COGT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,758,300
Market Cap $600M
Description
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found ...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.